3/25
06:23 am
alxo
TOLREMO Strengthens Scientific Advisory Board with Lung Cancer Expert Pasi A. Jänne [Yahoo! Finance]
Low
Report
TOLREMO Strengthens Scientific Advisory Board with Lung Cancer Expert Pasi A. Jänne [Yahoo! Finance]
3/9
01:50 pm
alxo
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 [Yahoo! Finance]
High
Report
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 [Yahoo! Finance]
3/8
07:33 am
alxo
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
High
Report
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
3/7
01:36 pm
alxo
Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday [Yahoo! Finance]
Medium
Report
Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday [Yahoo! Finance]
3/7
11:43 am
alxo
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its price target lowered by analysts at Stifel Nicolaus from $3.00 to $1.50. They now have a "hold" rating on the stock.
Low
Report
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its price target lowered by analysts at Stifel Nicolaus from $3.00 to $1.50. They now have a "hold" rating on the stock.
3/7
08:13 am
alxo
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
High
Report
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
3/6
05:21 pm
alxo
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
High
Report
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/6
04:01 pm
alxo
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
High
Report
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
3/6
09:45 am
alxo
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its price target raised by analysts at Piper Sandler from $8.00 to $9.00. They now have an "overweight" rating on the stock.
Medium
Report
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its price target raised by analysts at Piper Sandler from $8.00 to $9.00. They now have an "overweight" rating on the stock.
3/6
07:18 am
alxo
ALX Oncology Holdings Inc. (NASDAQ: ALXO) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock, up previously from $2.00.
High
Report
ALX Oncology Holdings Inc. (NASDAQ: ALXO) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock, up previously from $2.00.
3/5
09:02 am
alxo
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event [Yahoo! Finance]
Low
Report
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event [Yahoo! Finance]
3/5
08:00 am
alxo
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event
Medium
Report
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event
2/27
08:00 am
alxo
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
Low
Report
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
2/18
09:11 am
alxo
ALX Oncology to Host Virtual R&D Day on March 5, 2025 [Yahoo! Finance]
Medium
Report
ALX Oncology to Host Virtual R&D Day on March 5, 2025 [Yahoo! Finance]
2/18
08:00 am
alxo
ALX Oncology to Host Virtual R&D Day on March 5, 2025
Medium
Report
ALX Oncology to Host Virtual R&D Day on March 5, 2025
1/27
11:10 am
alxo
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its price target lowered by analysts at UBS Group AG from $4.00 to $2.20. They now have a "buy" rating on the stock.
Medium
Report
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its price target lowered by analysts at UBS Group AG from $4.00 to $2.20. They now have a "buy" rating on the stock.
1/24
10:33 am
alxo
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
1/24
08:02 am
alxo
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its price target lowered by analysts at HC Wainwright from $25.00 to $5.00. They now have a "buy" rating on the stock.
Medium
Report
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its price target lowered by analysts at HC Wainwright from $25.00 to $5.00. They now have a "buy" rating on the stock.
1/23
11:41 am
alxo
ALX Oncology stock falls 16% amid Phase 2 data update [Seeking Alpha]
Medium
Report
ALX Oncology stock falls 16% amid Phase 2 data update [Seeking Alpha]
1/23
08:00 am
alxo
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
Medium
Report
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
1/23
07:09 am
alxo
How Nike's new CEO plans to rebound from its worst year ever [Fortune]
High
Report
How Nike's new CEO plans to rebound from its worst year ever [Fortune]
1/22
04:01 pm
alxo
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
Medium
Report
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
1/22
09:00 am
alxo
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium
Medium
Report
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium
1/22
09:00 am
alxo
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium
Medium
Report
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium
1/22
08:00 am
alxo
ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors
Medium
Report
ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors